NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50436-0015-01 | 50436-0015 | METHYLPREDNISOLONE | METHYLPREDNISOLONE | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | July 26, 2023 | In Use | |
51144-0001-60 | 51144-0001 | Tucatinib | TUKYSA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | April 17, 2020 | In Use | |
51991-0797-98 | 51991-0797 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Subcutaneous | Aug. 7, 2017 | Jan. 31, 2024 | No Longer Used |
52584-0420-10 | 52584-0420 | Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 10.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | May 26, 2014 | Jan. 31, 2024 | No Longer Used |
54879-0003-08 | 54879-0003 | Dexamethasone | Dexamethasone | 0.5 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sept. 21, 1976 | In Use | |
54879-0027-11 | 54879-0027 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | May 29, 2019 | In Use | |
55390-0370-10 | 55390-0370 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 1, 2020 | In Use | |
55700-0952-65 | 55700-0952 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 11, 2022 | In Use | |
57664-0020-97 | 57664-0020 | Isotretinoin | Isotretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
57664-0021-97 | 57664-0021 | Isotretinoin | Isotretinoin | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
57664-0022-97 | 57664-0022 | Isotretinoin | Isotretinoin | 25.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
57664-0023-97 | 57664-0023 | Isotretinoin | Isotretinoin | 30.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
57664-0024-97 | 57664-0024 | Isotretinoin | Isotretinoin | 35.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
57664-0025-97 | 57664-0025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec. 29, 2020 | In Use | |
58118-5442-08 | 58118-5442 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan. 24, 2017 | In Use | |
58118-7500-08 | 58118-7500 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 13, 2018 | In Use | |
59923-0601-10 | 59923-0601 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 6, 2013 | In Use | ||
59923-0602-10 | 59923-0602 | Pamidronate Disodium | Pamidronate Disodium | 6.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 6, 2013 | In Use | ||
59923-0603-10 | 59923-0603 | Pamidronate Disodium | Pamidronate Disodium | 9.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug. 6, 2013 | In Use | ||
59923-0702-02 | 59923-0702 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 20, 2008 | In Use | |
59923-0702-05 | 59923-0702 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 20, 2008 | In Use | |
59923-0714-02 | 59923-0714 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | March 1, 2019 | In Use | |
59923-0715-05 | 59923-0715 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | March 1, 2019 | In Use | |
59923-0716-15 | 59923-0716 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 6, 2019 | In Use | |
59923-0721-60 | 59923-0721 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | March 1, 2020 | In Use |
Found 10,000 results in 2 milliseconds — Export these results